Loading...
•
Mar 31, 2025
Guardant Health Q1 2025 Earnings Report
reported financial results for the first quarter ended March 31, 2025
Key Takeaways
Guardant Health reported strong revenue growth of 21% in Q1 2025, driven by solid performance in oncology, screening, and biopharma & data segments. The company also increased its full-year 2025 revenue guidance.
Total revenue increased 21% to $203.5 million compared to the prior year period.
Oncology revenue grew 20% to $150.6 million, with a 25% increase in oncology test volume.
Screening revenue was $5.7 million, generated from approximately 9,000 Shield screening tests.
Biopharma & Data revenue increased 21% to $45.4 million.
Revenue by Segment
Forward Guidance
Guardant Health raised its full-year 2025 revenue guidance and provided updated expectations for oncology, screening, and biopharma & data revenue growth.
Positive Outlook
- Full year 2025 revenue guidance raised to $880 to $890 million, representing 19% to 20% growth.
- Oncology revenue expected to grow approximately 18% year over year in 2025.
- Oncology volume expected to accelerate to greater than 25% growth in 2025.
- Screening revenue expected in the range of $40 to $45 million, driven by Shield volume of 52,000 to 58,000 tests.
- Free cash flow burn expected to improve to $225 to $235 million for the full year 2025.
Challenges Ahead
- Total non-GAAP operating expenses expected to increase to $830 to $840 million.
- The increase in non-GAAP operating expenses is due to reinvestment of incremental Screening gross profit to accelerate commercial infrastructure build out.
- Free cash flow burn includes approximately $200 million of screening net cash burn.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...